Myeloablative transplantation of bone marrow (BM) engineered to express myelin oligodendrocyte glycoprotein (MOG) establishes central intrathymic tolerance and completely prevents MOG-induced experimental autoimmune encephalomyelitis (EAE) in mice. Here we asked whether non-myeloablative transplantation of MOG expressing BM (pMOG-bone marrow transplantation (BMT)) can also provide the same protection. Using stepwise reduction of irradiation doses, 275 cGy irradiation with pMOG-BMT protected 100% of mice from EAE development even with two subsequent re-challenge with MOG. Irradiation doses o275 cGy produced dose-dependent partial protection with significant disease protection still evident at 50 cGy. Splenocytes from 275 cGy recipients proliferated to MOG stimulation in vitro, indicating that MOG-reactive cells are present in the periphery but failed to induce disease. MOG-stimulated splenocytes produced little or no interleukin-17, interferon-g, granulocyte-monocyte colony stimulating factor and tumor necrosis factor-a compared with EAE control. Adoptive transfer of CD4 T cells from EAE-resistant mice into Rag2 À/À mice devoid of MOG expression resulted in MOG-induced EAE in B74% of mice. Treatment of EAE-resistant mice with anti-programmed death 1 (PD-1) monoclonal antibody-induced EAE in 67% of mice. We conclude that nonmyeloablative transplantation of self-antigen expressing BM induces robust peripheral tolerance that completely prevented EAE development. Our findings implicate clonal anergy and the PD-1 pathway in the maintenance of peripheral tolerance.
INTRODUCTION
Autologous bone marrow transplantation (BMT) as curative treatment is currently under clinical trials for a number of intractable autoimmune diseases including multiple sclerosis. Although shortterm clinical benefit and complete remission have been reported, relapses increase with time. 1 --5 Using myelin oligodendrocyte glycoprotein peptide 33 --55 (MOG 35À55 ) induced experimental autoimmune encephalomyelitis (EAE) as a model of multiple sclerosis, we have shown that transplantation of syngeneic bone marrow (BM) can be associated with disease remission but recipient mice retained susceptibility to EAE upon MOG 35À55 re-immunization. 6 Thus, data from human clinical trials and animal studies indicate that autologous/syngeneic BMT alone is insufficient to provide a cure. Transplantation of genetically modified hematopoietic stem cells using retroviral vectors has been used to treat human immunodeficiency disorders. 7 --9 In autoimmunity, using lethal-myeloablative pre-conditioning, we have demonstrated that transplantation of BM genetically engineered to express MOG provided EAE resistance in recipient mice, even after multiple immunization challenges 6 and showed central deletional tolerance as a mechanism of resistance.
Myeloablative irradiation is used to pre-condition patients for BMT of autoimmune diseases. 3,5,10 --12 As these diseases are generally non-lethal, a mortality rate of 5-10% 3,10,13,14 associated with myeloablative irradiation is not a viable option, even with improved clinical care that has reduced the mortality rate to o5%. 5, 12 Clearly, in using genetically modified BM to induce antigen-specific tolerance, a less toxic conditioning regime that can still facilitate potent disease resistance is needed. As low levels of molecular chimerism of B1% to B15% 6,15 --17 have been successful in inducing tolerance, harsh pre-conditioning may not be needed for optimal BM grafting to establish immune tolerance.
Here, we report in the MOG-induced EAE model that 275 cGy irradiation pre-conditioning for transplantation of BM encoding MOG (pMOG-BMT) provided 100% EAE resistance in recipient mice. At irradiation doses lower than 275 cGy, there is a dosedependent reduced protection with increasing incidence and disease severity. At 50 cGy irradiation, pMOG-BMT still provided significant disease protection compared with controls. CD4 T cells from disease-resistant mice transferred into Rag2 À/À mice and treatment of disease-resistant mice with anti-programmed death 1 (PD-1) monoclonal antibody resulted in EAE, implicating clonal anergy and the PD-1 pathway in peripheral tolerance.
RESULTS
275 cGy non-myeloablative pre-conditioning prevented EAE development whereas 50 cGy provided partial protection We have shown that pMOG-BMT with 1100 cGy lethal irradiation induced antigen-specific central intrathymic tolerance and prevented EAE development in recipient mice. 6 Here we investigated whether transplantation of pMOG-BM with lower doses of irradiation would provide a similar preventive effect. We used stepwise reduction of irradiation doses of 770, 550, 412, 275, 100, 50, 20 or 5 cGy. Similar to 1100 cGy, pMOG-BMT with 770, 550, 412 (data not shown) or 275 cGy prevented EAE development in 100% of mice ( Figure 1a ). With irradiation doses o275 cGy, there was dose-dependent partial protection, with a correlation coefficient (R 2 ) of 0.8654 between irradiation dose and mean clinical score. As irradiation dose decreased, disease incidence (Table 1) and severity progressively increased (Figure 1a) . Transplantation of pMOG into non-irradiated recipients resulted in EAE similar to EAE control (data not shown). At 50 and 100 cGy, pMOG-BMT provided EAE protection (Pp0.001) compared with control groups (Figure 1a) . The mean day of onset with 50 cGy was also significantly delayed compared with control groups (50 cGy vs EAE control, Po0.001; 50 vs 275 cGy irradiated control, Po0.05). However, at 100 cGy the difference did not reach significance because only 3 out of 10 mice developed disease. Cumulative scores also showed dose-dependent reduction as irradiation dose increased, with 50 cGy being the lowest irradiation dose providing significant protection (Figure 1b) . These data show that pMOG-BMT provided complete disease protection at 275 cGy and partial but significant protection at 50 cGy.
Mice receiving 275 cGy irradiation or greater were resistant to disease development upon re-immunization with MOG whereas mice receiving o275 cGy produced mild EAE To determine whether mice remained disease resistant with pMOG-BMT, mice that remained disease free 14 weeks after the Figure 1 . Irradiation dose of 275 cGy combined with pMOG BMT provided complete EAE protection even after a second MOG immunization whereas lower irradiation doses provided dose-dependent partial protection. (a) Mice that received 275, 100, 50, 20 and 5 cGy and pMOG-BMT were immunized with MOG 35À55 peptide to induce EAE. Mice from 275 cGy sub-lethal irradiation group were completely prevented from disease development whereas EAE disease control and 275 cGy irradiation control groups developed severe disease. Decreasing irradiation doses resulted in development of more severe disease as reflected by increasing clinical scores (means±s.e.m.). Correlation coefficient (R 2 ) for irradiation dose and mean clinical score is 0.8654. (b) Cumulative scores for each group showed a decreasing trend with increasing irradiation doses. Tables in Figures 1a and b represent statistical significance between curves as assessed by a premutation test described in Materials and Methods. Significant P-values o0.05 indicated by shaded boxes. (c) Mice that remained disease free after first MOG immunization were re-immunized with MOG 35À55 peptide. Mice from 275 cGy sub-lethal irradiation group remained disease free whereas mice from 100 cGy irradiation group developed mild EAE and control mice developed severe EAE. (d) Cumulative scores for irradiation groups from (c) are significantly lower than EAE control. Data are mean±s.e.m. ns, not significant. *770, 550 and 412 cGy gave the same result as 275 cGy.
first MOG immunization were re-immunized with MOG 35À55 peptide. Following re-immunization, mice receiving 770, 550, 412 or 275 cGy remained disease free (100%) whereas 86% of mice receiving 100 cGy, and 100% of mice receiving 50 and 20 cGy developed EAE (Table 1) . However, disease severity in the 50 and 20 cGy-treated mice was reduced (Supplementary Figure S1 ) with the 100 cGy group showing significant reduction in mean clinical and cumulative scores compared with EAE control (Figures 1c and d) . Some disease-resistant mice that received X275 cGy and immunized with MOG 35À55 peptide a third time remained disease resistant (see Figure 5c under treatment of anti-PD-1 antibody breaks tolerance).
Histological analysis of the central nervous system We stratified disease outcomes as disease free, mild EAE (clinical score 1 --2) and severe EAE (clinical score X3). Histological analysis of the central nervous system reflected these categories; mild EAE having limited cellular infiltrates and mild demyelination (Figure 2a) , severe EAE having extensive cellular infiltration and demyelination ( Figure 2b ) and disease-free mice showing no cellular infiltrate and no loss of myelin ( Figure 2c ). As assessed by hematoxylin and eosin and Luxol fast blue staining, all treatment groups that received irradiation pre-conditioning and pMOG-BMT had significantly lower cellular infiltration and myelin loss, respectively, compared with EAE and 275 cGy irradiation control groups ( Table 1 ). The 275 cGy group showed no cellular infiltration and demyelination (Table 1) . Dose-dependent molecular chimerism levels in relation to irradiation dose Because all experiments carried out in this study use sorted green fluorescent protein (GFP) þ pMOG-BM cells and GFP expression can be used as a marker for molecular chimerism of MOG protein expression, 6 chimerism can be assessed based on GFP expression. Indeed, BMcells transduced with pMOG were shown to co-express GFP and MOG protein (Figure 3a ). There was a dose-dependent trend in the level of molecular chimerism as irradiation dose increased with strong correlation coefficient (R 2 ) of 40.9 in peripheral blood, inguinal lymph nodes (iLN), BM, thymus and spleen (Figure 3b ). Positive trends of molecular chimerism were also reflected in antigen-presenting cells such as Figure S2) in spleen, iLN and thymus and in CD4 þ , CD8 þ and CD19 þ cell lineages in iLN (Figure 3c ). pMOG-BMT into non-irradiated recipients resulted in molecular chimerism levels similar to 5 cGy group (data not shown).
Dose-dependent reduction of in vitro immune responses to MOG Similar to the trend in clinical scores, in vitro splenocyte proliferation response to MOG peptide followed a negative dose-dependent manner such that as irradiation dose increased, proliferation decreased. In contrast to 1100 cGy disease-resistant and naive mice where their splenocytes failed to proliferate in response to MOG peptide even at 100 mg ml À1 , 6 splenocytes from 275 cGy mice proliferated to MOG peptide at 100 mg ml
À1
. These results indicate the presence of peripheral MOG-reactive T cells in disease-resistant mice ( Figure 4a ). Mice that received 770, 550 or 412 cGy also showed similar proliferation to MOG peptide as 275 cGy mice (data not shown). On the other hand, splenocytes from mice that received irradiation o275 cGy proliferated to MOG peptide stimulation even at low concentration whereas those from 275 cGy without BMT proliferated similarly to EAE alone control (data not shown). In addition, there is a positive dose-dependent proliferation as MOG 35À55 peptide concentration increased (Figure 4a ).
Serum anti-MOG antibody levels also demonstrated a similar trend as splenocyte proliferation with the levels of anti-MOG 35À55 antibody decreasing with increasing irradiation dose ( Figure 4b ). The mean absorbance levels of antibody for 275 and 100 cGy were significantly lower compared with EAE control (Po0.001), and 20 and 5 cGy cohorts (Po0.01). Antibody levels at 50 cGy was also significantly lower compared with EAE control (Po0.01) and 5 cGy (Po0.05).
In vitro stimulated MOG-reactive splenocytes from diseaseresistant mice produced little or no pro-inflammatory cytokines In response to in vitro MOG 35À55 peptide challenge, splenocytes from 275 cGy mice produced little or no interleukin (IL)-17, interferon-g, granulocyte-monocyte colony stimulating factor and tumor necrosis factor-a compared with EAE control. In contrast, splenocytes from 5 cGy mice produced higher levels of these cytokines whereas 50 cGy mice produced intermediate levels ( Figure 4c) . None of the groups produced significantly differing levels of the Th2-associated cytokines IL-4 and IL-10 compared with EAE control mice.
Transfer of CD4 T cells from EAE-resistant mice into immunodeficient Rag2
À/À mice induces EAE To determine whether the MOG-reactive T cells from EAE-resistant mice can induce disease, we transferred these cells into immunodeficient Rag2 À/À mice. Splenocytes from 770 to 550 cGy mice that remained disease resistant after two rounds of MOG immunization were used to isolate total CD4 T cells. These CD4 T cells were injected into Rag2 À/À mice and immunized 4 weeks later to induce EAE. Five naive mice were immunized as EAE control. All five mice from the EAE control group developed disease (100%) whereas B26% (5 out of 19 mice) of the transferred CD4 T-cell group developed a very late-onset disease 4100 days after MOG immunization ( Figure 5a and Table 2 ). Rag2 À/À mice that remained disease free after the first immunization with MOG peptide received a second immunization of MOG peptide. The immunization was controlled with five naive mice immunized with MOG peptide at the same time. Approximately 64% (9 out of 14 mice) of total CD4 T-cell group and 100% of EAE control mice developed disease ( Figure 5b and Table 2 ). EAE was a lethal disease in the Rag2 À/À experiment as the majority (13 out of 14) of diseased Rag2 À/À mice developed a rapid lethal score 5 disease with the average day between disease onset and reaching score 5 being 3.4±1.6 days after MOG immunization (Table 2) . Previous studies by Zhang et al. 18 also reported fatal EAE disease in Rag2 À/À mice after transfer of splenocytes from EAE diseased mice. Thus, the overall disease incidence for total CD4 T-cell transfer was B74% (14 out of 19; Table 2 ). Compared with EAE control after the first immunization, there was a significant delay in the onset of EAE in Rag2 À/À mice that received total CD4 T cells ( Figure 5a and Table 2 ). Upon re-immunization of disease-resistant Rag2 À/À mice (n ¼ 14) from the first immunization, the mean day of disease onsets was not significantly different compared with EAE control, although it was significantly shorter than that from first immunization ( Figure 5b and Table 2 ). We detected B6% of CD4-positive cells from splenocytes but were unable to detect CD8 and CD19-positive cells, consistent with successful adoptive CD4 T-cell transfer into Rag2 À/À mice.
Treatment of anti-PD-1 antibody breaks tolerance The PD-1 pathway controls peripheral T-cell tolerance. 19, 20 To investigate its role, EAE-resistant mice were chosen from BMT groups receiving irradiation of 275 cGy or above that were resistant to EAE induction after two rounds of MOG 35À55 immunization. On the same day as these mice were immunized for the third time, they were also given 500 mg per mouse of anti-PD-1 monoclonal antibody or 500 mg per mouse of control rat immunoglobulin G (IgG). Every 2 days thereafter, 250 mg of anti-PD-1 monoclonal antibody or control IgG per mouse were injected for a further five times. Five naive mice were also immunized as EAE control at the same time. IgG control mice remained disease free and all mice from EAE control group developed disease whereas 4 out of 6 (B67%) of the anti-PD-1-treated group developed disease (Figure 5c and Table 3 ). In this group, 2 out of the 4 diseased-mice developed a clinical score of X3 (Table 3) with the remaining 2 mice developing milder disease. The cumulative EAE score of the anti-PD-1 group was significantly higher compared with the IgG control group (Po0.001) but less than the EAE control group (Po0.05) with the IgG control being significantly lower compared with EAE control (Po0.001; Figure 5d ). Histology of spinal cord showed mononuclear cell infiltration with demyelination in the anti-PD-1-treated diseased mice confirming the clinical outcomes whereas disease-free mice showed no cellular infiltration or demyelination (data not shown).
No significant changes in the proportion of CD4 þ Foxp3 þ regulatory T cells Similar to our previously reported data, 6 we did not detect any significant changes in the proportion of CD4 þ Foxp3 þ regulatory T cells in the spleen, iLN and thymus across the different irradiation doses (Supplementary Figure S3) .
DISCUSSION
Genetic manipulation of the BM compartment to induce immune tolerance is a powerful strategy to treat immunological diseases.
6,21 -- 24 We have previously shown that transplantation of BM cells genetically modified to express MOG led to ectopic MOG expression in BM-derived cells that induced central intrathymic immune tolerance and complete EAE resistance. 6 Using EAE models, other have reported similar observation by transplanting BM cells expressing full-length phospholipid protein under myeloablative pre-conditioning or BM cells encoding a At the end of day 137, the remaining disease-resistant mice from (a) were re-immunized with MOG and observed for a further 117 days. (c) EAE-resistant mice were chosen from BMT groups, which had complete protection from EAE development after two rounds of MOG immunization. On day 0 of the third immunization, 500 mg of anti-PD-1 mAb was injected intraperitoneal (i.p.), followed by 5 Â 250 mg of anti-PD-1 mAb injected i.p. every other day. Control IgG at the same dosages was used in the control group. EAE control mice were generated at the same time. (d) Cumulative score of anti-PD-1-treated group is significantly higher than IgG control group whereas significantly lower than EAE control group. Data are mean±s.e.m. different MOG epitope (MOG 40À55 ) under busalfan-induced partial myeloablation. 25, 26 Some of these studies used high-dose irradiation, similar to those used to pre-condition BM recipients in stem cell transplantation for leukemias. However, high-intensity irradiation is associated with unacceptable mortality rates for treating autoimmune diseases that are typically non-lethal. 3,5,10,12 --14 Recently, it was reported that non-myeloablative autologous BMT to treat multiple sclerosis produced a positive outcome. 4 However, alemtuzumab that provides a beneficial outcome in multiple sclerosis patients was also included in the conditioning regimen. 27 Here, we carried out step-down irradiation dose experiments to assess the effect of antigen-specific BMT under non-myeloablative conditioning regimes. We found that 275 cGy pre-conditioning for pMOG-BMT established peripheral tolerance that protected 100% of mice from developing EAE, even with three rounds of MOG immunization, showing that our approach induced potent immune tolerance in recipient mice. At an irradiation dose as low as 50 cGy, which produces no human fatality nor severe side effects, pMOG-BMT still provided significantly diminished disease severity even after re-immunization with MOG.
We observed a positive dose-dependent relationship between irradiation dose and molecular chimerism levels assessed by eGFP expression. With myeloablative pre-conditioning molecular chimerism levels in the thymus, spleen and iLN ranged from B15 to 30%. 6 Under non-myeloablative pre-conditioning (275-5cGy), molecular chimerism levels in these organs ranged Bo1 --6%. The findings are consistent with reports that low levels of molecular chimerism may be sufficient to promote tolerance. 6,15 --17 Dendritic cells 28 --32 and CD19 þ cells 33 --36 have important roles in inducing tolerance and a dose-dependent relationship between irradiation dose and molecular chimerism levels is observed in these cells Our data suggest that there is a 'level of autoantigen availability' or molecular chimerism 'threshold' in which pMOG-BMT provided complete EAE protection; however, as the availability of autoantigen reduces below that 'threshold', the degree of tolerance decreased accordingly.
In our previous study using 1100 cGy pre-conditioning together with pMOG-BMT that protected 100% of mice from EAE development, we reported central intrathymic deletion of MOG-reactive T cells and complete absence of MOG-reactive splenocytes in the periphery. 6 In contrast, in this study although 100% of mice that receiving X275 cGy pre-conditioning with pMOG-BMT remained diseased free even after re-immunization with MOG, splenocytes from these mice responded to stimulation with high concentrations of MOG in vitro whereas splenocytes from mice receiving irradiation doses o 275 cGy readily proliferated to MOG peptide at lower concentrations.
To determine the mechanisms of tolerance and to assess the potential of MOG-reactive splenocytes from disease-resistant mice to induce disease, we adoptively transferred CD4 T cells from these mice into immunodeficient Rag2 À/À mice. The adoptive transfer resulted in EAE development in the majority (74%) of these mice confirming the presence of disease-inducing MOGreactive T cells in the original disease-resistant mice. We also noted a significant delay in disease onset after the first immunization consistent with reports that peripherally tolerized T cells require several weeks to reverse T-cell unresponsiveness. 37, 38 Our findings are also consistent with reports that antigen presence is required to maintain peripheral tolerance. 37 --40 The observation that MOG-reactive CD4 T cells that are non-reactive in vivo can be rendered reactive in a MOG antigen-free environment of Rag2 À/À mice also suggests clonal anergy in vivo as one possible mechanism of peripheral tolerance. The suggestion is consistent with the report that functionally impaired CD4 þ T cells can persist in vivo following induction of peripheral tolerance 43 and that in vivo clonal anergy can be reversed in the absence of antigen, such that the T cells are able to proliferate extensively to a new challenge with the antigen in question. 44 Our observation that splenocytes from diseaseresistant mice that proliferated to in vitro MOG challenge, produced little or no IL-17, interferon-g, granulocyte-monocyte colony stimulating factor and tumor necrosis factor-a, major inflammatory cytokines implicated in EAE 41 --45 is also consistent with the report that antigen-specific CD4 þ T cells that survive after the induction of peripheral tolerance possess an intrinsic lymphokine production defect. 46 The PD-1 pathway has a crucial role in peripheral tolerance induction and maintenance as mice with deletion of PD-1 gene developed systemic autoimmunity. 47 Injection of PD-1 neutralizing monoclonal antibody into disease-resistant mice resulted in the majority (67%) of the mice developing EAE whereas none of the IgG controls developed disease. Although we failed to detect any significant changes in proportion of CD4 þ Foxp3 þ T cells, it remains to be determined whether antigen-specific Tregs were generated in this model.
In contrast to our finding of a lack of MOG antibody response in mice that had been lethally irradiated, 6 we found MOG antibody in the mice that had received non-myeloablative irradiation. The levels of anti-MOG antibody detected in these mice also reflected a similar trend whereby the levels of anti-MOG antibody increased as irradiation dose decreased. The data suggest preservation of T-dependent helper function for antibody production or incomplete deletion of MOG-reactive B cells.
Taken together, our data suggest a correlation between levels of molecular chimerism/antigen availability to the degree of tolerance induced. Our suggestion is consistent with observations of Liston et al. 48 who presented data that correlated tolerance with the level of antigen expression. Our results point to incomplete central intrathymic deletion of MOG-reactive T cells resulting in 'escape' of MOG-reactive cells to the periphery. However, these cells failed to cause disease in mice that received X275 cGy. We suggest that at 275 cGy and above, T-cell clones with low affinity T-cell receptor against MOG escaped central tolerance and are tolerized by peripheral mechanisms, but were able to proliferate in vitro at high MOG concentration. At lower irradiation doses where molecular chimerism is reduced, MOGreactive T cells with higher affinity T-cell receptor against MOG also escaped.
Experimentally, spontaneous autoimmune diseases are suggested to be 'stem cell disorders' because transplantation of BM cells from autoimmune-prone animals into normal mice leads to the development of autoimmune diseases and thus autologous BMT cannot be used as a treatment option. 49 On the other hand, antigen-induced autoimmune disease models require immunization of relevant antigen in animals with particular genetic background. 50 In addition, both forms of diseases are subjected to environmental influences, 51 indicating that both genetic and environment factors are important elements involved in autoimmunity. Immunologically, the failure of self-tolerance, either due to genetic and/or environmental factor, constitutes the basis for autoimmunity. Our approach of transplanting genetically modified BM clearly induces potent immune tolerance where animals remained disease resistant even after three rounds of MOG immunization. We conclude that antigen-specific BMT induces robust peripheral immune tolerance under non-myeloablative pre-conditioning in which 275 cGy provided complete disease-resistance whereas significant partial protection was observed at irradiation dose as low as 50 cGy. Although MOG-reactive cells were detected in the periphery of disease-resistant mice in vitro, these cells are capable of inducing disease following adoptive transfer to immunodeficient Rag2 À/À mice. It has been reported that peripheral antigen expression is required to maintain peripheral tolerance. 37 --40 As MOG-reactive T cells can be activated in the antigen-free Rag2 À/À environment, the data are suggestive of clonal anergy as another possible mechanism of tolerance. Further, we identified the PD-1 pathway as another peripheral mechanism implicated in maintaining tolerance of autoreactive cells in vivo. Although it remains possible that other peripheral tolerance mechanisms may also have been recruited to maintain tolerance and disease resistance in vivo, our data indicate that using this strategy, total eradication of peripheral autoreactive cells is not necessary as induced peripheral tolerance mechanisms are sufficient to control these cells from causing disease. Our findings have implications for the treatment of organ-specific autoimmune diseases where the causative self-antigens are known. However, this strategy will most probably not contribute to the treatment of systemic autoimmune diseases such as systemic lupus erythematosus where the autoantibodies are increasing steadily and in which even allowing for antigen drive, the genome-dependent autoimmune polyreactivity would seem to hinder the autoantigen tolerization approach.
MATERIALS AND METHODS Mice
Female C57BL/6 mice were from Monash Animal Services (MAS, Australia).
Rag2
À/À mice were from Walter and Eliza Hall Institute animal facility. Animals were housed in specific pathogen-free environment (Monash Medical Centre Animal Facilities MMCAF Australia). Syngeneic BM donors were 5--6-week-old female C57BL/6 mice. All studies were performed with approval of local Animal Ethics Committee.
Retroviral transduction of BM and transfer
Generation and viral titer determination of retroviral vectors encoding MOG were as described previously. 6, 21 BM cells collected from donor mice were transduced with retrovirus as described, 6 with the percentage of transduction of B12%. Briefly, donor mice were treated with 5-fluorouracil (140 mg kg À1 body weight) 3.5 days before BM harvest and cultured in rmIL-6 (10 ng ml À1 , R&D Systems, Minneapolis, MN, USA) and rmSCF (50 ng ml À1 , R&D Systems). After 24 h, cells were transduced with retrovirus and cultured for a further 3 --4 days before transferring sorted eGFP þ BM cells into recipient mice that had been subjected to 2 Â 385, 550, 412, 275, 100, 50, 20 or 5 cGy total body irradiation. Approximately 40 000 eGFP þ cells were transferred into each recipient. After 8 weeks to allow for BM reconstitution, mice were immunized with MOG 35À55 peptide to induce EAE. A group of mice (275 cGy irradiation control) that received 275 cGy alone without BMT was used as irradiation control. BM cells transduced with retroviral vectors encoding MOG were stained for MOG protein expression. Briefly, eGFP-positive cells were sorted and stained with monoclonal mouse anti-MOG Ab (clone 8-18C5) for 1 h at room temperature. After three washed with Hank's balanced salt solution þ 1% fetal calf serum, goat anti-mouse Alexa 594 (Invitrogen, Carlsbad, CA, USA) was added and incubated for 40 min. Cells were washed twice and viewed under a fluorescence microscope (Nikon eclipse TE2000-U, Melville, NY, USA). All steps were conducted in the dark.
EAE induction and clinical evaluation
A total of 200 mg of the encephalitogenic peptide MOG 35 --55 (GL Biochem, Shanghai, China) was emulsified in complete Freund's adjuvant (Sigma-Aldrich, St Louis, MO, USA) supplemented with 4 mg ml
À1
Mycobacterium tuberculosis in 200 ml was injected subcutaneously into both femoral regions. Mice were immediately injected intravenously with 350 ng pertussis toxin (Sigma-Aldrich) and again 48 h later. Animals were monitored daily for 6 weeks and neurological impairment scored on an arbitrary clinical score: 0, no clinical sign; 1, limp tail; 2, limp tail and hind limb weakness; 3, complete hind limb paresis; 4, complete hind and fore limb paresis; 5, moribund or death. 6, 52 As recommended by the Animal Ethics Committee, mice were euthanised when they reached a clinical score of 3. For re-immunization experiments, mice that remained disease free for 6 weeks during the clinical observation period were given an additional 8 week of rest before subsequent re-immunized. In anti-PD-1 experiment, EAE-resistant mice that were completely protected from EAE development after two rounds of MOG immunization were chosen from groups that received pMOG-BMT pre-conditioned by 275 cGy or above. On the day of the third immunization, 500 mg of anti-PD-1 (RMPI-14) 53 or control rat IgG (Sigma-Aldrich) was injected intraperitoneal followed by five extra doses of 250 mg per mouse of anti-PD-1 or control rat IgG every 2 days. Cumulative score was calculated by averaging the sum of the daily clinical scores for each mouse per group.
Histology
The brain and spinal cord were removed and fixed in 10% formalin. Cervical, thoracic and lumbar segments of each spinal cord were embedded in paraffin. Between 8 --16 sections, each at least 20 mm apart, were examined. The extent of inflammation and demyelination was evaluated on tissue sections (5 mm) with hematoxylin and eosin to assess inflammation and Luxol fast blue for demyelination. Histological sections were scored blind. For inflammation, evaluation was performed using hematoxylin and eosin-stained sections and scored as follows: 0, no inflammation; 1, cellular infiltrate only in the perivascular areas and meninges; 2, mild cellular infiltrate in parenchyma; 3, moderate cellular infiltrate in parenchyma; 4, severe cellular infiltrate in parenchyma. Myelin loss was assessed as pale staining with Luxol fast blue and scored as follows: 0, no demyelination; 1, mild demyelination; 2, moderate demyelination and 3, severe demyelination.
Splenocyte proliferation assay and cytokine detection
Analyses were performed when mice were killed, either at the end point of an experiment or upon reaching a clinical score of 3, total splenocytes from were cultured at 500 000 cells per well in complete RPMI supplemented with 10% fetal calf serum, L-glutamine, penicillin and streptomycin. Cells were stimulated with 1 --100 mg ml À1 MOG 35À55 peptide. Concanavalin A (10 mg ml À1 final concentration) was used as positive control and cells without peptide stimulation as background. After 72 h incubation at 37 1C with 10% CO 2 , 20 ml of [ 3 H]Thymidine (2 mCi/well; MP Biomedicals, Seven Hills, NSW, Australia) was added to each well and incubated for a further 16 h. [ 3 H]Thymidine incorporation was determined by Packard Tri-Carb 1900TR liquid scintillation analyser (Packard Inc., Ramsey, MN, USA). All cultures were in triplicate and proliferation data presented as stimulation index. In some experiments, 72 h culture supernatants stimulated with 100 mg ml À1 MOG 35À55 peptide were collected for cytokine detection (Bender Medsystems, eBioscience, San Diego, CA, USA).
MOG-specific antibody detection MOG-specific antibody was measured by enzyme-linked immunosorbent assay (ELISA) as described. 6 Sera were collected at end-point of each experiment, and tested at 1:100 dilution in 96-well plates coated with 5 mg ml À1 of MOG 35À55 . The mean absorbance of triplicates was calculated with deduction of absorbance from non-coated wells.
Transfer of total CD4 splenocytes into Rag2 knockout mice
Mice from 770 to 550 cGy that were EAE resistant after two rounds of MOG immunization were used as splenocyte donors. Total CD4 T cells (purity 495%) were negatively isolated by depletion of magnetically labeled non-CD4 T cells using magnetic antibody cell sorting system. A total of 1 Â 10 6 cells per mouse were injected intravenously into Rag2 À/À mice.
